DENDRITIC CELL BASED VACCINATION W/ IDIOTYPE FOR AMYLOIDOSIS & POST TRANSPLANT

基于树突状细胞的淀粉样变性独特型疫苗接种

• 批准号: 6265003
• 负责人: MARTHA Q LACY
• 金额: $ 2.01万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265003
• 关键词: amyloidosis; blood /lymphatic neoplasm; clinical research; clinical trial phase I; dendritic cells; gene therapy; human subject; human therapy evaluation; neoplasm /cancer therapy; neoplasm /cancer vaccine; transplantation

The specific aim of this study is to see if dendritic cell-based vaccination to idiotype will induce clinical remission in malignant plasma proliferative diseases. As of February 16, ten patients have been enrolled; four have completed the vaccinations. It is too soon to comment on results, however, we have not seen any patients develop progressive disease. None have yet gone off the study. At least one appears to be achieving a remission. We are planning to write a follow-up trial that will utilize low-dose immunomodulatory drugs as adjuvants to the dendritic cell-based vaccines. An RO-1 based on this work will be submitted to the National Cancer Institute by the June 1 deadline. So far, it is too early to have submitted any publications referable to this work, however, I am planning to submit an abstract to the International Multiple Myeloma workshop as well as to the American Society of Hematology meeting.

本研究的具体目的是观察基于树突状细胞的独特型疫苗接种是否会诱导恶性血浆增殖性疾病的临床缓解。 截至2月16日，已有10名患者入组; 4人已完成疫苗接种。 现在对结果发表评论还为时过早，但是，我们尚未看到任何患者出现疾病进展。 还没有人退出研究。 至少有一个似乎正在缓解。 我们正计划撰写一项后续试验，该试验将利用低剂量免疫调节药物作为树突状细胞疫苗的佐剂。 基于这项工作的RO-1将在6月1日截止日期前提交给国家癌症研究所。到目前为止，提交任何与这项工作相关的出版物还为时过早，然而，我计划向国际多发性骨髓瘤研讨会和美国血液学学会会议提交摘要。